First Genital Chlamydia Vaccine Proves Safe in Phase I Trial
A vaccine for Chlamydia is potentially in sight. A team of British and Danish scientists recently completed a test of the vaccine they developed for the sexually transmitted infection and found it to be safe and effective, CNN reported on Tuesday.

The trial included 35 women between the ages of 19 and 35 and was conducted at London’s Hammersmith Hospital, the study published in the Lancet Infectious Diseases medical journal on Monday said. None of the women experienced serious side effects.

“The vaccine showed the exact immune response we had hoped for and which we have seen in our animal tests. The most important result is that we have seen protective antibodies against Chlamydia in the genital tracts,” one of the study’s authors, Frank Follmann, the Head of the Department at the Statens Serum Institut (SSI) in Denmark, said in a statement on the institute’s website.

“Our initial trials show them preventing the Chlamydia bacteria from penetrating the cells of the body,” Follmann continued. “This means that we have come a lot closer to a vaccine against Chlamydia.”

Chlamydia is considered the “most prevalent” sexually transmitted infection, according to Imperial College, and there are 131 million cases every year. But even that large number is “likely to be underestimated,” the statement said, because three out of every four cases don’t include symptoms.

Dr. S●●●●●●e C●●●●●●●y and 10 others like this1 share